Meningioma Systematic Reviews [Neurosurgery Wiki]

This page is read only. You can view the source, but not change it. Ask your administrator if you think this is wrong.
====== Meningioma Systematic Reviews ======

Eight [[electronic database]]s/registries were [[search]]ed to identify eligible [[meningioma]] [[Systematic Review]]s with and without [[meta-analysis]] published between January [[1990]] and December [[2020]]. [[Article]]s concerning [[spinal meningioma]] were excluded. [[Report]]ing and [[methodological quality]] were assessed against the following [[tool]]s: Preferred Reporting Items for Systematic Reviews and Meta-Analyses ([[PRISMA]]), A Measurement Tool to Assess systematic Reviews ([[AMSTAR 2]]), and Risk Of Bias in Systematic reviews ([[ROBIS]]).

116 Systematic Reviews were identified, of which 57 were SRMAs (49.1%). The mean PRISMA score for SRMA was 20.9 out of 27 (SD 3.9, 77.0% PRISMA adherence), and for SR without meta-analysis was 13.8 out of 22 (SD 3.4, 63% PRISMA adherence). Thirty-eight studies (32.8%) achieved greater than 80% adherence to PRISMA. Methodological quality assessment against AMSTAR 2 revealed that 110 (94.8%) studies were of critically low quality. Only 21 studies (18.1%) were judged to have a low risk of bias against ROBIS.

The reporting and [[methodological quality]] of meningioma [[evidence]] syntheses were poor. Established [[guideline]]s and [[critical appraisal]] [[tool]]s may be used as an adjunct to aid methodological conduct and reporting of such [[review]]s, in order to improve the [[validity]] and [[transparency]] of [[research]] that may influence clinical practice
((George AM, Gupta S, Keshwara SM, Mustafa MA, Gillespie CS, Richardson GE, Steele AC, Zamanipoor Najafabadi AH, Dirven L, Marson AG, Islim AI, Jenkinson MD, Millward CP. Meningioma systematic reviews and meta-analyses: an assessment of reporting and methodological quality. Br J Neurosurg. 2022 Oct 20:1-8. doi: 10.1080/02688697.2022.2115008. Epub ahead of print. PMID: 36263847.)).
----
Updated Systematic Review on the Role of Brain Invasion in Intracranial Meningiomas: What, When, Why? 
((Brunasso L, Bonosi L, Costanzo R, Buscemi F, Giammalva GR, Ferini G, Valenti V, Viola A, Umana GE, Gerardi RM, Sturiale CL, Albanese A, Iacopino DG, Maugeri R. Updated Systematic Review on the Role of Brain Invasion in Intracranial Meningiomas: What, When, Why? Cancers (Basel). 2022 Aug 27;14(17):4163. doi: 10.3390/cancers14174163. PMID: 36077700; PMCID: PMC9454707.)).
----
The Emerging Relevance of H3K27 Trimethylation Loss in Meningioma: A Systematic Review of Recurrence and Overall Survival with Meta-Analysis
((Lu VM, Luther EM, Eichberg DG, Morell AA, Shah AH, Komotar RJ, Ivan ME. The Emerging Relevance of H3K27 Trimethylation Loss in Meningioma: A Systematic Review of Recurrence and Overall Survival with Meta-Analysis. World Neurosurg. 2022 Jul;163:87-95.e1. doi: 10.1016/j.wneu.2022.04.048. Epub 2022 Apr 16. PMID: 35439620.)).
----
Seizure prophylaxis in meningiomas: a systematic review and meta-analysis
((Delgado-López PD, Ortega-Cubero S, González Bernal JJ, Cubo-Delgado E. Seizure prophylaxis in meningiomas: a systematic review and meta-analysis. Neurologia (Engl Ed). 2022 Jun 30:S2173-5808(22)00036-0. doi: 10.1016/j.nrleng.2022.03.002. Epub ahead of print. PMID: 35781420.)).
----
A systematic review and meta-analysis of the association between cyproterone acetate and intracranial meningiomas
((Lee KS, Zhang JJY, Kirollos R, Santarius T, Nga VDW, Yeo TT. A systematic review and meta-analysis of the association between cyproterone acetate and intracranial meningiomas. Sci Rep. 2022 Feb 4;12(1):1942. doi: 10.1038/s41598-022-05773-z. PMID: 35121790; PMCID: PMC8816922.)).
----
Volumetric growth of residual meningioma - A systematic review
((Gillespie CS, Taweel BA, Richardson GE, Mustafa MA, Keshwara SM, Babar RK, Alnaham KE, Kumar S, Bakhsh A, Millward CP, Islim AI, Brodbelt AR, Mills SJ, Jenkinson MD. Volumetric growth of residual meningioma - A systematic review. J Clin Neurosci. 2021 Sep;91:110-117. doi: 10.1016/j.jocn.2021.06.033. Epub 2021 Jul 5. PMID: 34373014.))
----
[[Incidental intracranial meningioma]]s: a systematic review and meta-analysis of prognostic factors and outcomes
((Islim AI, Mohan M, Moon RDC, Srikandarajah N, Mills SJ, Brodbelt AR, Jenkinson MD. [[Incidental intracranial meningioma]]s: a systematic review and meta-analysis of prognostic factors and outcomes. J Neurooncol. 2019 Apr;142(2):211-221. doi: 10.1007/s11060-019-03104-3. Epub 2019 Jan 17. Erratum in: J Neurooncol. 2019 Sep;144(2):427-429. PMID: 30656531; PMCID: PMC6449307.)).